MK-417

MK-417 is a thienothiopyran-2-sulfonamide small molecule developed as a **topical carbonic anhydrase inhibitor** for the treatment of glaucoma. It acts by inhibiting human carbonic anhydrase II in the nonpigmented epithelium of the ciliary body, which results in reduced aqueous humor production and lowered intraocular pressure. Compared to traditional oral carbonic anhydrase inhibitors, MK-417 is designed for topical application, minimizing systemic side effects while effectively reducing intraocular pressure for glaucoma management. Clinical trials indicate MK-417 is a potent and well-tolerated ocular hypotensive agent in this drug class[2].